BioArctic & Eisai
11 shared events · Importance 5 · Last updated May 25, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
BioArctic is a research-based biopharma company that licenses its proprietary technologies and drug candidates, including Leqembi and BrainTransporter, to Eisai for global development and commercialization of Alzheimer's treatments.
Business
BioArctic: BioArctic receives royalties from Leqembi sales; Q2 2026 royalty of SEK 179 million represents 10% growth, boosting revenue outlook.
Eisai: Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, driving its revenue and partnership with Biogen.
Jul 29, 2026 · 6 articles
Business
BioArctic: As the inventor of Lecanemab and a partner in its development and commercialization, BioArctic stands to benefit significantly from the projected sales, receiving royalties and milestone payments. This event positively impacts its financial outlook.
Eisai: Eisai, as the primary developer and commercializer of Lecanemab, presented the sales simulation, indicating strong future revenue growth for the company. This positively impacts its financial projections and market position.
May 25, 2026 · 7 articles
Business
BioArctic: BioArctic held its Annual General Meeting, making several key resolutions including dividend payment, board re-elections, and approval of an incentive program, which directly impacts its corporate governance and shareholder value.
Eisai: Eisai is BioArctic's partner for Leqembi, responsible for regulatory interactions and commercialization globally, indicating a significant collaboration for BioArctic's key product.
May 28, 2026 · 9 articles
Business
BioArctic: BioArctic issued 5,000 Class B shares to participants in its stock option program, increasing its total number of shares and votes.
Eisai: Eisai is mentioned as BioArctic's partner in developing and commercializing Leqembi.
May 29, 2026 · 6 articles
Business
BioArctic: BioArctic is the company issuing the Q2 report and hosting the investor presentation. The event is routine and does not change its outlook.
Eisai: Eisai is BioArctic's partner for Leqembi commercialization. The Q2 report may include updates on Leqembi sales, but no specific impact is announced.
Aug 19, 2026 · 6 articles
Business
BioArctic: BioArctic is a key party, contributing its BrainTransporter technology and leading drug candidate generation. The collaboration expands its pipeline into oncology, potentially enhancing its growth prospects.
Eisai: Eisai is BioArctic's partner for Leqembi, but is not directly involved in this collaboration. The event does not materially affect Eisai.
Aug 19, 2026 · 6 articles
Tech
BioArctic: Greta Duréel has consulted for BioArctic, but no direct impact from this study.
Eisai: Greta Duréel has consulted for Eisai, but no direct impact from this study.
Aug 12, 2026 · 6 articles
Business
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
May 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how BioArctic and Eisai interact across events, view sentiment trends, and discover connected entities.
Open Dashboard